Released Nov 9, 2021, after the close
10-Q filed Nov 10, 2021, 41 days after period end · 0001564590-21-055843
Q3 2021 · 10-Q
Revenue$8.52M$8.52M −52.2% vs Q3 2020−69.6% vs Q2 2021
Net Income-$30.90M-$30.90M N/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.67-$0.67 N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$34,674,000N/M
Operating Cash Flowderived-$24,406,000N/M
Margins · derived
Operating margin-407.1%−347.5 pt vs Q3 2020
Net margin-362.8%−459.0 pt vs Q3 2020
What the release said
The release
Same quarter
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Revenue | $8.52M | $17.82M | $12.28M | $7.84M |
| Net Income | -$30.90M | $17.14M | -$12.91M | -$10.24M |
| EPS Diluted | -$0.67 | $0.45 | -$0.56 | -$21.26 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR